Literature DB >> 28007399

Evaluating the methylation status of CXCR4 promoter: A cost-effective and sensitive two-step PCR method.

Valentina Bianchessi1, Andrea Lauri2, Vera Vigorelli1, Martina Toia1, Maria Cristina Vinci3.   

Abstract

The chemokine receptor CXCR4 plays a key role in the bone marrow microenvironment maintenance and in the hematopoietic stem and progenitor cells migration. In addition, CXCR4 is expressed in a broad spectrum of solid tumors where its methylation state has been recently proposed as a biomarker for cancer prognosis. To evaluate methylation status of CXCR4 promoter we developed a sensitive, accurate, specific and cost-effective two-step PCR method that does not require any specific equipment other than a conventional real-time PCR instrument. The principle of the technique relies on a novel normalization strategy which allows the detection and quantification of small methylation differences among pre-amplified DNA samples deriving from low amount of starting material. In addition, the analysis of melting curve profiles of PCR products provides additional information about the methylation status of CpG sites in between the primers. Finally, the principle of this technique can potentially be adapted for the investigation of the methylation status of any other DNA region.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CXCR4; DNA methylation; Epigenetics; Promoter; SYBR green; qPCR

Mesh:

Substances:

Year:  2016        PMID: 28007399     DOI: 10.1016/j.ab.2016.12.016

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  1 in total

1.  Abnormal DNA Methylation Induced by Hyperglycemia Reduces CXCR 4 Gene Expression in CD 34+ Stem Cells.

Authors:  Vera Vigorelli; Jessica Resta; Valentina Bianchessi; Andrea Lauri; Beatrice Bassetti; Marco Agrifoglio; Maurizio Pesce; Gianluca Polvani; Giorgia Bonalumi; Laura Cavallotti; Francesco Alamanni; Stefano Genovese; Giulio Pompilio; Maria Cristina Vinci
Journal:  J Am Heart Assoc       Date:  2019-05-07       Impact factor: 5.501

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.